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Tumour Targeting of the Anti-Ovarian Carcinoma X Anti-CD3/TCR 
Bispesific Monoclonal Antibody OC/TR and its Parental MOvl8 
Antibody in Experimental Ovarian Cancer
OTTO C. BOERMAN », JACOBAG. TIBBENU, LEON F.A.G. MASSUGER2, ROLAND A.M.J. CLAESSENS *
and FRANS H.M. CORSTENSi
I Department of Nuclear Medicine, 2Department of Obstetrics and Gynaecology, University Hospital Nijmegen, The Netherlands
Abstract. The anti-tumour x anti-T-cell bispecific monoclonal has been proposed as a new approach of cancer treatment
antibody (biMAb) OC/TR is a biologically produced biMAb (1,2). In this concept a biMAb reactive with a tumour cell on
combining the anti-ovarian carcinoma activity of the MOvlS one hand and an effector cell on the other is used to retarget
MAh with anti-CD3/T-ce!l receptor (TCR) complex activity. In the cytotoxic activity of the effector cell towards tumour cells.
this study, the in vitro binding characlerisiics of the OCITR T-cell lysis of a target cell is generally restricted to major
biMAb and its tumour targetting potential in nude mice with histocompatibility complex-associated (MHC)
Hela tumours was studied\ Scatchard analysis revealed that the recognition, When a biMAb provides the physical linkage
affinity constant of the biMAb was 7 times lower than the affinity between a CD3/T-cell receptor (TCR) complex and a tumour
of the parental MOvlS antibody. Uptake o f the OCITR antibody cell, specific tumour cell lysis can occur (3,4).
in the Hela xenografts in nude mice was significantly higher than In most preelinica! studies investigating the therapeutic
the tumour uptake of an irrelevant control antibody, indicating potential of biMAbs, activated effector cells coated with
that the radioiodinated OCITR biMAb specifically localized in biMAbs have been administered locoregionally (5-7), The
the tumour xenografts. However; tumour uptake was significantly first clinical studies have also focused on
lower than the tumour uptake of the parental MOvlS antibody. infusion of redirected effector cells. In a study in glioma
This reduced tumour uptake most likely is a result of its reduced patients biMAb-coated cells were administered intracranially
affinity. We conclude that, despite the loss of bivalent tumour (8), while Bolhuis and coworkers (CJ) administered ex vivo
cell binding, the biMAb OC/TR cun still specifically localize in 
tumours. This indicates that the first prerequisite of an effective 
therapeutic approach using systenucaily applied hi MAh can be 
met. Whether the interaction with human T-cells will a ffect the 
tumour huge ting potential of the biMAb in patients remains to 
he investigated.
Redirecting effector cells of the immune system towards 
tumour cells with bispecific monoclonal antibodies (biMAbs)
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expanded and activated autologous peripheral blood 
lymphocytes (PBLs) intraperitonealiy in ovarian cancer 
patients. However, only a minority of cancers can be treated 
locoregionally. In addition, in vitro studies have shown that 
CD3/TCR complexes on preaetivaled PBLs that had earlier 
been engaged in target cell lysis are no longer able to lyse 
another cell. Only biMAbs binding newly expressed 
CD3/TCR complexes were able to reengage the T-cell in 
another lytic cycle (10), This observation indicates that the 
administration of precoated effector cells could only have 
limited efficacy. Therefore, in vivo targeting of high doses of 
biMAbs to the tumour site in order to redirect the lytic 
activity of T-cells at the tumour site seems to be a more 
attractive approach. However, tumour targeting of anti- 
tumour x anti-T-cell biMAbs might be hampered by the loss 
of bivalent tumour cell binding, and/or the interaction of the 
biMAb with peripheral T-cells. The present study investigates 
the tumour targeting potential of an anti-tumour x anli-CD3
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Ta b le I. In vitro bin ding ch a ra cterist i cs of th e antibody prep a ra lions.
Immun ore active fraction Affinity constant (M-1)
anti-gp38 anti-CD3/TCR Displacement Scatchard
MOvlS IgG 61 % 3.0 x 10« 20 x 10«
Anti-CD3 IgG — 81 % — —
MOvI 8 x anti~CD3 biMAb 55 % 76 % 7.5 x '107 2,9 x 10«
Anti-CD3/TCR x mismatch n .d .* 69 % ------ —
1,1 not detectable
biMAb OC/TR in a nude mouse model,
The biMAb OC/TR combines the anti-ovarian carcinoma 
activity of the MOvlS MAb with anti-CD3/TCR complex 
activity (II). In patients with epithelial ovarian cancer 
radioiodinated M O v l8 has been shown to localize specifically 
in ovarian carcinoma lesions (12,13). The biMAb OC/TR was 
obtained after fusion of the M O v l8-producing hybridoma 
cells with spleen cells from a BALB/c mouse immunized with 
a human T-cell clone (1.1,14). In vitro studies indicated that 
this biMAb is able to induce efficient tumour cell lysis (11,14). 
In nude mice with i.p. growing NIH:OVCAR-3 ovarian 
carcinoma cells, tumour growth inhibition was achieved by 
treating the mice with IL-2 and activated PBL coated with 
OC/TR F(ab*)2 (7). In addition, a phase I/II study in ovarian 
cancer patients treated with OC/TR coated autologous PBL 
and IL-2 has shown some remarkable responses (9). We plan 
to investigate the feasibility of a therapeutic approach based 
on the systemic administration of OC/TR biMAb in ovarian 
cancer patients. Therefore, we studied the in vitro binding 
characteristics and the in vivo tumour targeting potential of
i.v. administered OC/TR biMAb in a nude mouse model*
1ZO
Materials and Methods
Monoclonal antibodies* The MOvI8 antibody (IgCq ) recognizes a 38 kD 
cell surface glycoprotein (gp38) antigen expressed on most ovarian 
carcinomas (15) . The gp38 antigen was identifie cl as a folate binding 
protein (16-18). M0vl8 is also reactive with adenocarcinomas of the 
fallopian tube, endometrium and cervix (19).
The biMAb OC/TR (IgGi x IgG|) is produced by a trioma cell line 
obtained after fusion of the MOv 18 hybridoma with spleen cells from a 
BALB/c mouse immunized with a human T-eell clone (11,14). The 
biMAb was purified from trioma culture supernatant on a MONO-S 
cation exchange column (Pharmacia, Woerden, the Netherlands) as 
described previously (14). Inherent to (lie biological biMAb production 
process an IgG with an intact anti-CD3 binding site and a heavy-light 
chain pairing mismatch is produced. This *anti-CD3 x mismatch biMAb' 
was also purified from the trioma supernatant and used as a control 
antibody in the biodis tribu tion studies. Neither the OC/TR antibody nor 
the control antibody cross reacts with murine T-cells. The antibody 
preparations were prepared and supplied by Centocor Europe B.V. 
(Leiden, the Netherlands).
»
Cell lines. The HeLa human cervix carcinoma cell line (MOv 18-positive) 
and the Jurkat human aeutc T-eell leukemia cell line (CD3-positive) 
were obtained from the American Type Culture Collection. Cells were
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Figure 1 .A. Homologous displacement assay Jbr MOv 18 ( O ) and OCITR 
( •  ), B, Scatchard plot of radioiodinated MOv JtS ( O ) and OCITR ( •  ) 
binding to Hela cells.
cultured in RPMI-1640-based medium (Gibco, Paisley, UK) 
supplemented with 10% fetal calf serum.
Radiolabelling and quality control. The antibody preparations were 
labelled with 1251 or 13II using the enzymobead method (BioRad, 
Richmond, CA), according to the manufacturer’s instructions.
Briefly, 50 |.ig of IgG were mixed with 20 [il 0.5 M sodium phosphate (pH
2170
Boerman et al: Bispecific Monoclonal Antibody in Experimental Ovarian Cancer
26
20
-ST*o
* 15
o
ttf
♦-*a
Ï J
o
E
a
10
0
A
I'
6 8 10 12 14
tim» post Injection (days)
25
B
20
©>©
T3
Oo
3
10
0
0 8 10 12 14-
tlmo post in|oa)lon (days)
Figure 2. Tumour uptake (A) and blood levels (IS) of radioiodinated 
MOv IgG ( O )> OC/TR IgG ( •  ) and the control (unti-CI>3 a* 
mismatch) biMAb ( i l ) after intravenous administration in mice 
subcutaneously hearing ovarian carcinoma.
7.2), 50 jil enzymobead suspension and 500 |iCi 1251 (Amersham 
International, UK) or 1311 (Medgenix, Fleurus. Belgium) . 'Hie reaction 
was initialed by adding D( + ) glucose lo*a final concentration of 0,3%. 
Following 15 minutes incubation, the reaction mixture was applied on a 
Sephadex G-25 column (Pharmacia, Sweden) and eluted with PBS, 0.5% 
BSA. The fractions containing the labelled antibody were pooled and 
used for in vivo studies within 16 hours. 'The amount of free iodine in the 
preparations was determined by instant thin layer chromatography 
(ITLC).
The immunoreaelivity against the ovarian enreinoma-associnted 
antigen gp38 (MOv 18 reactivity) and/or against the CD3/TCR complex 
(anli-CD3/TCR reactivity) of the radioiodinated antibody preparations 
was determined on live Hela cells or Jurkat cells, respectively. A fixed 
amount of labelled antibody (10,000 cpm) was incubated with increasing 
numbers of cells (0.6 x UK> - 10 x KK1) in 0.5 ml binding buffer (RPMI 
medium, 0.5% BSA, 50 mM HEPES, 0,05% NaNj). After 4h of 
incubation at 4°C\ the radioactivity in the pellet was counted in a we II- 
lype gamma counter. A duplicate of the lowest eel] concentration was 
incubated in the presence of excess unlabellcd antibody to correct for 
nonspecific binding. 'The data were graphically analysed in a modified 
Lineweaver-Burke plot: a double inverse plot derived from the
Tabic lia, 'Tissue distribution of intravenoitsly administered 125J- MOvlS
IgG in nude mice with s.v. Hela tumours (% ID/g, mean ± SD, n~4).
Organ
Days post injection
I 3 7 14
Blood 15.5 ± 2.6 12.3 ± 1.4 10.3 ± 1,3 3.7 ± 1.4
Muscle 1.5 ± 0.2 1.1 ± 0.1 0.9 ± 0.1 0.3 ± 0.1
Liver 3.9 ± 1,0 2.7 ± 0.5 2,6 ± 0.2 1.0 ± 0.4
Intestine 1.9 ± 0.2 1.3 ± 0.2 1,1 ± 0.2 0.4 ± 0.1
Kidney 4,8 ± 0.9 3.5 ± 0.2 3,0 ± 0,3 LI ± 0.4
Tumour 12.0 ± 1.8 18.2 ± 2.9 18.0 ± 2,4 13,5 ±0.8
Table IU>, Tissue distribution of intravenously administered 12*1- OC/TR
IgG in nude mice with s.c. I Fela tumours (%' IF)Iff, mean ± SI) ,  n~4).
Organ
Days post injection
1 3 7 14
Blood 13.9 ± 1.2 12.8 ± 1.8 10,7 ± 2,3 4.9 ± 1.2
Muscie 2.2 ± 0.9 1.4 ± 0.2 1.0 ± 0.2 0.5 ± 0.1
Liver 4.7 ± 1.3 3.6 ± 0.7 2,6 ± 0.7 1.1 ± 0.3
Intestine 2,4 ± 0.9 L7 ± 0.3 1.2 ± 0.2 0.5 ± 0.2
Kidney 5.1 ± 1.9 3.7 ± 0.7 3.1 ± 0.8 1.4 ± 0.3
Tumour 14,1 ± 6.7 13,4 ± 2,0 14.3 ± 1.6 8.1 ± L3
Table He. Tissue distribution of intravenously administered MU- tuUi-Cl)3
x u I ist natch I g ( i in nude m ice i vit I i s.c. Hela tomoi trs ( vn ■ I Dig, meatt ± *S7),
n=tf).
Days post injection
u i gan
1 3 7 14
Blood 14.4 ± 2.8 12.3 ± 1.7 10.0 ± 2.2 5.9 ± 2.4
Muscle 1.6 ± 0.2 1.2 ± 0.1 0.9 ± 0.2 10.6 ± 0.2
Liver 4.2 ± 1.0 3.2 ± 0.6 2.8 ± 0,6 1.7 ± 0.9
Intestine 2.0 ± 0.5 1,6 ± 0.2 1.2 ± 0.2 0.7 ± 0.3
Kidney 4,3 ± 0.8 3.8 ± 0.7 3.1 ± 0.6 L8 ± 0,8
Tumour 5.6 ±1,1 5.5 ± 0,7
A*K ß)VJWi
S 1 -i - 13* * 4 1 I  I « t 3 *♦* 2 Ik N » '  <è* i 1
conventional binding plot (specifically bound activity versus cell 
concentration). The immunoreaclive fraction was calculated by linear 
extrapolation to the Y-axis abscissa as described by Lindnio et al (20).
In vitro binding assays* The relative affinities of the unlabellcd antibody 
préparations were compared in a homologous displacement assay. A 
serial dilution of cold antibody (0.01 - 100 |ig/ml) was incubated with
A n t i c a n c e r  R e s e a r c h  75; 2159-2174 ( iw s )
Heia cells (K x 10$ eells/vial) in the presence of a fixed amount of tracer 
antibody (15,000 cpm) in binding buffer. After overnight incubation at 
4“C the cells were centrifuged (5 min, 2000 g), the supernatant was 
aspirated and the activity in the pellet was determined. The fraction of 
maximal bound tracer antibody (absence of cold competitor antibody) 
was plotted verst is the concentration of cold antibody added. Relative 
affinity constants were calculated as the reciprocal concentration of 
unlabelled antibody required for 50% displacement of the radiolabelled 
antibody (21).
The affinities of the radioiodinated MOv 18 and OC/TR preparations 
were compared in a Scatchard analysis (22). Briefly, live Iiela cells were 
washed once with cold binding buffer and incubated with serially diluted 
(10 ■ 10,000 pM) 1251-labeIIed antibody. Each vial was counted in the 
gamma counter to determine the total amount of activity added. For 
each antibody concentration the nonspecific binding was determined by 
incubating a duplicate sample in the presence of at least 500 fold excess 
of unlabelled antibody. After overnight incubation at 4“C cells were 
centrifuged (5 min, 2000 g), the supernatant was aspirated and the 
activity in the pellet was determined, The data were analysed by 
nonlinear weighted regression analysis .
Subcutaneous ovarian carcinoma model. The subcutaneous (s.c.) tumour 
model was established in nude mice by s.c. injection of 1 x It)7 ITela cells. 
Tumours were resected aseptieally, minced into small pieces of 2-3 nim 
diameter and serially transplanted subeutaneously at the left lumbar 
region of female BALB/e nude mice. Four to six weeks after 
transplantation, when lumours measured approximately 5 mm in 
diameter, mice were used for biodistribution studies.
Biodistribution studies. Female nude mice with s.c. Hela xenografts 
received 0.2 ml of a solution containing both 1251 - MOv 18 IgG 
(10Ci/10|ig) and l^ll - control IgG (mismatch x anti - CE>3) (10 
fiCi/H) fig) via the tail vein. Another set of animals received a solution 
containing a mixture of both 1251 - OC/TR IgG (10 |iCi/10 (Ag) and 13*1 - 
control IgG (anti-CD3 x mismatch) (10 [iCi/JO |ug) via the tail vein. At 
least four micc were used per data point. The biodistribution of the 
radioiodinated antibodies was monitored during 14 days p.i,, allowing 
nol only the comparison of tumour accumulation (0 - 3 days), but also of 
tumour retention (3 - 14 days p.i.) of the biMAb and its parental 
antibody. The mice were bled under ether anaesthesia at I, 3, 7 and 14 
days post injection (p.i.). After cervical dislocation mice were dissected. 
Blood, liver, kidneys, intestine, muscle and tumour were removed. 
Tissues were weighed and radioactivity was measured in a well-type 
ganimacounler (LKB-Wallae, Finland). A correction for scatter of l-^ il in 
(he 1251 channel was made. 'Tissue uptake was expressed as percentage of 
the injected dose per gram tissue (% ID/g).
Statistical analysis. Results are presented as mean ± standard deviation. 
Differences in tissue uptake of the three antibody preparations (MOvlH, 
OC/TR, control) were evaluated by Student’s l-test,
Results
Rculiolabelling and quality control The labeling efficiency of 
the radio iodinations according to the enzymobead method 
was always between 60 and 80%. ITLC analysis of the 
radioiodinated preparations showed that more than 95% of 
the iodine-la be Is was protein-bound after Sephadex G-25 gel 
filtration. The immunoreactive fractions of the radiolabelled
(01% and 81%, respectively). In addition, the control 
antibody (anti-CD3/TCR'x mismatch) revealed an immuno­
reactive fraction of W%  for the anti-CD3/TCR reactivity, 
combined with nondetectable anti-tumour reactivity, 
confirming its monospecific reactivity.
In vitro binding assays. The displacement of ^-labelled 
MOvlS binding to Hela cells with cold M O vl8 is shown in 
Figure 1Ä. In this assay the unlabelled MOv 18 antibody 
displays an apparent affinity of 3.0 x 10# M-i. The apparent 
affinity of the biMAb OC/TR in the same experiment is 4 
times lower (7.5 x 107 M-l).
The Scatchard analysis of the tumour cell binding of both 
antibody preparations is depicted in Figure IB. The affinity 
constant of the radioiodinated MOvlS antibody was 2.04 x 10C) 
M-i, while the affinity of the OC/TR biMAb was 7 times 
lower: 2.86 x 10^  Mr1. This would indicate that the loss of 
bivalent antigen binding of the bispecific OC/TR antibody 
causes a reduction of the affinity by a factor 7. The x-axis 
intercepts indicate that M Ovl8 could bind a maximum of 5,3 
x 10f> antigenic determinants on each Hela cell, while OC/TR 
could bind 4.5 x 10(l determinants, confirming that both 
antibodies recognize the same epitope on the Hela cells.
Biodistribution studies, The blood clearance data are 
presented in Figure 2B. The blood clearance of the OC/TR 
biMAb was similar to the clearance of the parental M Ovl8 
antibody and the control antibody. The elimination half-life 
(T172ß) of the three antibody preparations was () days. The 
label uptake of the normal tissues examined was lower than 
the blood level, but clearance of the radiolabel from these 
tissues followed the same pattern (Table II). Both for M Ovl8 
and OC/TR the tumour uptake was higher than the blood 
level from three days p.i. onwards. In contrast, for the control 
antibody (anti-CD3/TCR x mismatch biMAb) tumour uptake 
was lower than the blood level at all time points. Tumour 
uptake of MOv 18 and OC/TR pi a te au ed between 3 and 7 
days p.i. at 18 ± 3 and 14 ± 2 % ID/g, respectively (Figure 
2À). At all time points, tumour uptake of both MOv 18 as well 
as OC/TR was significantly higher (p<0,05) than the tumour 
uptake of the control antibody, indicating that both antibody 
preparations showed specific, i.e. antigen-binding dependent, 
tumour localization, In addition, MOv 18 tumour uptake was 
significantly higher than OC/TR tumour uptake from 3 days 
p.i, onwards (p<0.05).
Discussion
The present study shows that the bispecific MOv 18 x anti- 
CD3/TCR MAb OC/TR specifically localizes in human
preparations used in the biodistribution studies are presented ovarian carcinoma xenografts in nude mice. However, the
in Table I. The anti-tumour reactivity (55%) and the anti- tumour uptake of the OC/TR biMAb was significantly lower
CD3 reactivity (76%) of the bispecific MAb OC/TR were in than the tumour uptake of the parental MOv 18 antibody,
the same range as the reactivity of the parental antibodies This reduction in tumour uptake can not be ascribed to a
2172
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more rapid blood clearance of the biMAb, since the blood Acknowledgements 
clearance of both antibodies was identical. Most likely, the
« i  i *
reduced tumour uptake of the biMAb is a result of its 
reduced affinity. Several studies in nude mouse models have 
demonstrated that antibody affinity is one of the important 
factors that determine tumour accumulation (23,24). This 
relationship is elegantly demonstrated in the comparative 
biodistribution experiments of a series of six second 
generation anti-TAG72 antibodies in nude mice with LS174T 
xenografts (25). It is known that the affinity of a monoclonal 
antibody as calculated from a Scatchard analysis is dependent 
not only on the antibody used, but also on other experimental 
conditions, e,g, antigen density on the target cell (26), assay 
volume (27) and ionic strength (28). Therefore, the absolute 
value of the affinity constant of an antibody has only limited 
value. This could also explain the fact that the Ka for M O v l8
from our Scatchard analysis is significantly 
different from the Ka reported by Miotti el a I (15). Their 
determination on OvCa432 cells under different assay 
conditions revealed a 10 times lower affinity constant (2.0 x
108 M-l.
Nevertheless, our results show that the OC/TR biMAb has 
a relatively lower affinity than the M O vl8 antibody. Our 
observation that the loss of bivalency causes a reduction in 
affinity by a factor 4-7 is in line with other reports comparing 
the affinity of monovalent and bivalent antibody preparations
(29,30). Van Dijk et al (29) studied the biodistribution of the 
anti-RCC x anti-CD3 biMAb in RCC xenografted nude mice. 
Tumour uptake of the biMAb was not significantly different 
from the tumour uptake of the parental anti-RCC antibody. 
From their data it appeared that the tumour uptake of an 
anti-tumour antibody is more dependent on antibody size (/ c. 
the blood clearance rate) than antibody affinity. However, in 
this study tumour uptake was monitored until 4K hr p.i., and
■'••ences in tumour retention between both 
antibody preparations could not be evaluated.
In patients the biodistribution of i.v. administered OC/TR 
biMAb might be significantly altered by the interaction of the 
biMAb with T-ceils. However, it is difficult to study this 
phenomenon with this biMAb in an animal model, not only 
because nude mice lack mature T-eelis, but also because the 
OC/TR biMAb does not cross react with murine T 
lymphocytes. It would be interesting to study the tumour 
uptake of an anti-T-eell x anti-tumour biMAb in a syngeneic 
model.
In conclusion, our data indicate that the biMAb OC/TR 
can preferentially localize in MOv 18-positive tumours. Its 
reduced affinity as compared to the parental MOv 18 antibody 
most likely caused decreased tumour uptake. As indicated in 
the introduction, systemic administration of biMAbs may 
have some important advantages in trying to redirect 
endogenous T-cells towards a tumour. A clincial study to 
investigate the tumour targeting potential and the therapeutic 
efficacy of OC/TR F(alV)2 in ovarian cancer patients has been 
initiated (31).
The authors arc grateful to Mr G. Gruiters, Miss Y. Brom und Mr H. 
Eikholt for their technical assistance in the animal experiments.
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